How Clinical Trials Work

In 1747, a British ship surgeon named James Lind conducted what many consider the first clinical trial. Scurvy was killing sailors on long voyages. Lind selected 12 scurvy patients, divided them into groups, and gave each group different treatments: seawater, vinegar, spices, citrus fruits. The citrus group recovered dramatically. It was a simple observation that changed medicine forever: some treatments work better than others, and the only way to know is to compare them directly.

The short answer

Clinical trials are controlled experiments that test whether new medical treatments are safe and effective. They follow a standardized sequence: Phase I tests safety in a small group, Phase II tests effectiveness and refines dosing, Phase III compares the new treatment against the current standard in large groups, and Phase IV monitors long-term effects after approval. Every trial is overseen by an ethics committee and designed to generate reliable, unbiased results that regulators can use to decide whether to approve a treatment.

The full picture

Why clinical trials exist

Every approved drug on the market today exists because it was tested in clinical trials. Before the 20th century, treatments were based on tradition, anecdote, and the intuition of individual physicians. Many were useless or harmful. The randomized controlled trial, pioneered in the mid-20th century, introduced a simple but powerful idea: the best way to know if a treatment works is to compare groups of patients who receive different treatments, randomly assigning them to minimize bias.

This approach revealed that some widely used treatments were ineffective. In one famous example from the 1960s, a trial showed that the popular antiarrhythmic drug lidocaine actually increased mortality in heart attack patients. Without systematic testing, such harmful treatments could have continued being prescribed for decades.

Today, clinical trials are the foundation of evidence-based medicine. Regulatory agencies like the FDA in the United States and the EMA in Europe require substantial evidence from clinical trials before approving new treatments.

The four phases of clinical trials

Phase I is the first time a treatment is tested in humans. The primary goal is safety. Researchers give the treatment to a small group (typically 20 to 80) of healthy volunteers or, in cancer trials, patients with advanced disease. They start with a very low dose and gradually increase it, watching carefully for side effects.

Phase I trials answer questions like: What is the highest dose people can tolerate? What side effects occur? How does the body process the drug?

About 70% of drugs move past Phase I, according to estimates from Tufts Center for the Study of Drug Development.

Phase II tests whether the treatment actually works. Researchers give the treatment to a larger group (typically 100 to 300) of patients who have the condition the drug is meant to treat. They continue monitoring safety but also look for preliminary evidence of effectiveness.

Phase II trials often compare different doses to find the one that balances efficacy with acceptable side effects. About 33% of drugs move past Phase II.

Phase III is the definitive test. The treatment is given to large groups (typically 1,000 to 3,000 or more) and compared against the current standard treatment or a placebo. This is where researchers prove that the treatment works better than or as well as existing options.

Phase III trials are usually randomized and double-blinded: participants are randomly assigned to treatment or control groups, and neither the participants nor the researchers know which group is which until the trial ends. This prevents conscious or unconscious bias from influencing results.

Phase III trials are the primary basis for regulatory approval. About 25% to 30% of drugs move past Phase III.

Phase IV happens after the treatment is approved and on the market. Researchers monitor its effects in much larger populations over longer timeframes, looking for rare side effects or benefits that didn’t appear in earlier trials. This ongoing surveillance is called pharmacovigilance.

How trials are designed

Every clinical trial has a detailed protocol that specifies exactly how it will be conducted. Key elements include:

Eligibility criteria define who can participate. These include age, diagnosis, disease stage, prior treatments, and overall health. Criteria are designed to ensure the trial produces useful results and to protect participant safety. Excluding pregnant women, for example, protects both the participant and the fetus from unknown risks.

Randomization assigns participants to treatment or control groups by chance, like flipping a coin. This helps ensure that the groups are similar in age, disease severity, and other factors. Any difference in outcomes is more likely due to the treatment than to pre-existing differences between groups.

Blinding prevents bias from affecting results. In a single-blind trial, participants don’t know whether they’re getting the treatment or placebo. In a double-blind trial, neither participants nor researchers know. This prevents people from reporting or behaving differently based on what they think they’re getting.

Control groups receive either a placebo (an inactive substance) or the current standard treatment. Comparing against a placebo is ethically complicated when an effective treatment exists. In those cases, new treatments are usually tested against the existing standard rather than a placebo.

Endpoints are the outcomes researchers measure. Common endpoints include survival time, tumor shrinkage, symptom improvement, and quality of life measures. Defining endpoints before the trial starts prevents researchers from cherry-picking favorable results.

Who runs clinical trials

Clinical trials are sponsored by pharmaceutical companies, academic medical centers, government agencies, and sometimes individual physicians. Sponsors are responsible for designing the trial, funding it, and ensuring it follows the protocol.

Contract Research Organizations (CROs) manage the day-to-day operations of trials on behalf of sponsors. They coordinate with trial sites, collect data, and ensure compliance with regulations.

Clinical trial sites are the hospitals, clinics, and doctor offices where participants are enrolled and treated. Academic medical centers often run trials, but community physicians increasingly participate as well.

Institutional Review Boards (IRBs) or Ethics Committees review every trial before it starts and monitor it throughout. These independent groups ensure the trial is ethical, participants are adequately informed of risks, and vulnerable populations are protected. No trial can proceed without IRB approval.

What it means to participate

If you join a clinical trial, you’ll go through an informed consent process. This isn’t just signing a form. Researchers explain the trial’s purpose, procedures, risks, benefits, and alternatives. You can ask questions and take time to decide. You can also leave the trial at any time without penalty.

Participant safety is monitored throughout. An independent Data Safety Monitoring Board (DSMB) reviews accumulating data and can stop a trial early if the treatment is clearly working, clearly not working, or clearly causing harm.

Many trials compensate participants for their time and travel. Compensation varies widely: a Phase I trial involving multiple week-long stays might pay thousands of dollars, while a Phase III trial with a few outpatient visits might pay a few hundred.

The numbers game: why trials need so many people

Finding enough participants is one of the biggest challenges in clinical research. Many trials fail not because the drug doesn’t work, but because they couldn’t enroll enough patients to produce statistically meaningful results.

The reason trials need so many participants is that individual responses vary. Some patients improve on placebo, some get worse despite treatment, and some improve due to the treatment. To separate real effects from random variation, researchers need enough data points. A trial with 50 patients per group might miss a real 10% improvement. A trial with 500 per group can detect it.

This is why rare diseases face particular challenges. With few potential participants, trials are harder to run and take longer to complete.

Global trials and equity

Modern clinical trials are often multinational. A drug might be tested in the United States, Europe, and Asia simultaneously. This speeds enrollment and provides data on different populations.

But global trials raise equity concerns. Participants in lower-income countries may get access to treatments they couldn’t otherwise afford, but they may also be exploited if the resulting drugs aren’t made available or affordable in their country. Ethical guidelines require that trials provide some level of post-trial access to successful treatments.

Why it matters

Every modern medical treatment you or anyone you know has ever received was made possible by clinical trials. The antibiotics that treat your infections, the vaccines that protect you, the chemotherapy that fights cancer, the antidepressants that help with depression all exist because researchers tested them systematically and proved they work.

Clinical trials also protect you from ineffective or harmful treatments. Without rigorous testing, treatments based on theory or anecdote could remain standard for decades. The randomized controlled trial is one of the most important methodological innovations in the history of science.

But trials have limitations. They take years and cost hundreds of millions of dollars per successful drug. Many promising treatments fail in late stages after substantial investment. The participants in trials are not always representative of the broader population (elderly patients, people with multiple health conditions, and pregnant women are often excluded for safety reasons). This means drugs approved based on trial data may behave differently in the real world.

Common misconceptions

“Clinical trials are only for desperate patients.” Many trials enroll people with common conditions who have treatment options. Others test prevention strategies in healthy people. You don’t need to be out of options to participate.

“I might get a placebo instead of real treatment.” Placebos are used when no effective treatment exists or when it’s ethical to withhold treatment. In most trials testing serious conditions, the control group receives the current standard treatment, not a placebo. You’ll know before you enroll whether a placebo is involved.

“If I join a trial, I’m a guinea pig.” Participants in clinical trials receive careful monitoring, often more attention than in standard care. Every trial is reviewed by an ethics committee, and you can leave at any time. The goal is to test treatments while treating participants as ends in themselves, not means to an end.

“Clinical trials are unsafe.” All medical interventions carry risk, but clinical trials are designed to minimize and monitor those risks. The treatments have already been through extensive pre-clinical testing. Participants are closely monitored, and trials can be stopped early if safety concerns arise.

“Results are always kept secret.” Trial results must be reported to regulatory agencies. Many sponsors also commit to publishing results in peer-reviewed journals or public databases like ClinicalTrials.gov, which the FDA now requires for certain trials.